GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 Interest Coverage is 182.58 as of Mar. 2026, which is 57% below its 10-year median of 427.91. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 686 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks worse than 145772.45% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. GlaxoSmithKline Pakistan's
Operating Income
for the
three
months ended in Mar. 2026 was ₨4,263 Mil. GlaxoSmithKline Pakistan's Interest Expense for the
three
months ended in Mar. 2026 was ₨-23 Mil.
GlaxoSmithKline Pakistan's interest coverage for the quarter that ended in Mar. 2026 was 182.58.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. GlaxoSmithKline Pakistan Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for GlaxoSmithKline Pakistan's Interest Coverage or its related term are showing as below:
KAR:GLAXO's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.725 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
GlaxoSmithKline Pakistan Interest Coverage Related Terms
GlaxoSmithKline Pakistan Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
KAR:GLAXO vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Interest Coverage distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Interest Coverage of 182.58 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 57% below median its historical median of 427.91. Over the past decade, GlaxoSmithKline Pakistan's Interest Coverage has ranged from 49.33 to 1,235.84. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #999999 out of 686 companies in the Drug Manufacturers industry.
Is GlaxoSmithKline Pakistan's Interest Coverage too high?
GlaxoSmithKline Pakistan's current Interest Coverage of 182.58 is 57% below median its 10-year median of 427.91. Over the past 10 years, this metric has ranged from a low of 49.33 to a high of 1,235.84. The Drug Manufacturers industry median Interest Coverage is 12.73. GlaxoSmithKline Pakistan's value of 182.58 is 1334.8% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #999999 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #999999 out of 686 companies for Interest Coverage. This places GlaxoSmithKline Pakistan in the lower half of its industry. The industry median Interest Coverage is 12.73. GlaxoSmithKline Pakistan's value of 182.58 is 1334.8% above this benchmark. Historically, GlaxoSmithKline Pakistan's own Interest Coverage has ranged from 49.33 to 1,235.84 over the past decade. While the company's 10-year median is 427.91 vs. the industry median of 12.73, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Interest Coverage of 182.58 is 1334.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Interest Coverage is 182.58, which is 57% below median its own 10-year median of 427.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current Interest Coverage is 182.58, which is 57% below median its 10-year median of 427.91 and 1334.8% above the Drug Manufacturers industry median of 12.73. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Interest Coverage is 182.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
Interest Coverage: 182.58 (57% below median its 10-year median of 427.91)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 1334.8% above the Drug Manufacturers median (#999999 of 686)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
